JPRN-UMIN000010128Completed未知
Safety of the oxaliplatin readministration by the desensitization for metastatic colorectal cancer patients having oxaliplatin allergy - Safety of the oxaliplatin readministration by the desensitization for metastatic colorectal cancer patients having oxaliplatin allergy
Aichi Cancer Center Hospital0 sites10 target enrollmentStarted: February 28, 2013Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 10
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1 History of desensitization for oxaliplatin 2 history of oxaliplatin hypersensitivity Grade4 3 Uncontrollable diabetes mellitus 4 Regularly using steroid 5 Uncontrollable heart disease 6 Other severe complications such as renal failure liver failure and intestinal pneumonitis 7 Symptomatic CNS metastasis 8 Active bacterial or fungous infection 9 Massive pleural effusion or massive ascites 10 Active bleeding 11 Active double cancer 12 Patient evaluated to be inadequate by a attending doctor 13 Other conditions not suitable for this study
Investigators
Similar Trials
Completed
Phase 2
A phase II study of Oxaliplatin Reintroduction in patients pretreated with Oxaliplatin and Irinotecan for Advanced Colorectal CancerMetastatic colorectal cancerJPRN-UMIN000004884Japanese foundation for cancer research33
Completed
Phase 3
A randomized phase III study of oxaliplatin based chemotherapy versus combination chemotherapy of TS-1,irinotecan and bevacizumab as first line therapy for unresectable or recurrent colorectal cancerJPRN-UMIN000007834The Tokyo Cooperative Oncology Group450
Active, not recruiting
Phase 1
Safety of Intraperitoneal (IP) OXAliplatin (OXA) in Association With Systemic FOLFIRIBevacizumab Chemotherapy in Patients With Peritoneal Carcinosis ( IPOXA )Patients with peritoneal carcinosis of colorectal origin and uncertain resectability with an indication for systemic chemotherapy compatible with the FOLFIRI + bevacizumab combination.MedDRA version: 19.1Level: LLTClassification code 10052171Term: Peritoneal carcinomaSystem Organ Class: 100000004864EUCTR2016-002738-55-FRHospices Civils de Lyon
Not yet recruiting
Phase 2
A randomized, controlled, double-blind, multicenter clinical study of Huangqi Guizhi Wuwu Tang granules for the treatment of peripheral neurotoxicity induced by oxaliplatin in colorectal cancer chemotPeripheral neurotoxicity caused by oxaliplatin for colorectal cancer chemotherapyITMCTR2100005444Peng Cao
Completed
Phase 1
Phase I/II study of the combination of Oxaliplatin and S-1 in patients with advanced/recurrent colorectal cancerunresectable advanced/recurrent colorectal cancerJPRN-C000000443Outpatient Oncology Unit Kyoto University Hospital42